Iván Márquez-Rodas

Iván Márquez-Rodas is an expert in Oncology at Hospital General Universitario Gregorio Marañón (Spain). As of October 2026, ScienceLeadR ranks Iván Márquez-Rodas in the top 1% of experts worldwide for Melanoma and Skin Neoplasms. Iván Márquez-Rodas has authored 208 publications, the most recent in 2026, and is an investigator in 21 clinical trials, 3 of them ongoing. SLR score: 1,034 (community average: 125). How the SLR is computed.

Oncology

Subspecialties: Neurology - Public Health - Immunology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on October 19, 2026

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 2006 - 2026

Source: PubMed

Hospital General Universitario Gregorio Marañón

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 208

Citations

Citations: 24 463 1st author: 32 Last author: 22 Unique author: 0

Main journals

Best Journals

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title	Journal	Year
Exploring uncertainties in melanoma management: a Spanish multidisciplinary Delphi consensus. PMID 42886418 — melanoma, neoplasms, uncertainty, therapeutics	Clin Transl Oncol	2026
Mainstream and fast-track genetic testing in pancreatic cancer patients and its impact on treatment: our experience in a tertiary hospital in Spain. PMID 42541517 — tertiary care centers, research design, genes, pancreatic neoplasms, genetic testing, neoplasms, therapeutics, counseling, mutation	Fam Cancer	2026
Correction: Characterization of Melanoma of Unknown Primary in the Era of Immunotherapy and Targeted Therapy in Spain: Results from the Prospective Real World Study GEM 1801. PMID 42458140 — melanoma, neoplasms, immunotherapy, therapeutics	Clin Transl Oncol	2026
Real-world effectiveness of chemotherapy regimens after immunotherapy in patients with advanced melanoma in Spain: Results from the GEM1801 study. PMID 42411543 — melanoma, neoplasms, drug therapy, immunotherapy, immune checkpoint inhibitors, therapeutics, chemotherapy	Cancer	2026
Corrigendum to "Adjuvant immunotherapy in the modern management of resectable melanoma: current status and outlook to 2028": [ESMO Open 10 (2025) 104295]. PMID 41483632 — melanoma, neoplasms, immunotherapy	ESMO Open	2026

Clinical Studies 21

Sources: ClinicalTrials, EU CTIS

Synthesis

Study Chair: 1 Study Director: 1

By phase:

Phase 2 9

Phase 3 6

N/A 3

Phase 1 2

Phase 1/Phase 2 1

By status:

Completed 11

Active not recruiting 4

Terminated 4

Recruiting 2

By type:

Interventional 18

Observational 3

By Monocentric/Multicentric:

monocentric 1

multicentric2to4 0

multicentric5to9 2

multicentricup10 18

Main Topics

Nervous System Diseases 2

Skin and Connective Tissue Diseases 2

Ongoing Clinical Trials

3 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study	Phase	Status	Start
A Study of Subcutaneous Nivolumab Relatlimab FDC in Previously Untreated Metastatic or Unresectable Melanoma (RELATIVITY 127) 2022-500967-11-00 — pharmaceutical preparations, melanoma, nivolumab	Phase 3	Recruiting	2023
Encorafenib and biNimetinib Followed by CEmiplimab and FiAnLimab in Patients With BRAF Mutant melanOma and Symptomatic Brain Metastases NCT06887088 — brain neoplasms, melanoma, brain, neoplasms, neoplasm metastasis, therapeutics	Phase 2	Recruiting	2025
A Study of Subcutaneous Nivolumab Relatlimab Fixed dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma NCT05625399 — melanoma, nivolumab	Phase 3	Active not recruiting	2023

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS

Shopping Cart

System Maintenance Notice